Abstract
Background
Direct oral anticoagulants (DOACs) have demonstrated clinical benefits and better patient adherence over low-molecular-weight heparin (LMWH) in treating patients with cancer-associated venous thrombosis (CAT). We aimed to compare the cost-effectiveness of DOACs against LMWH in patients with CAT from the perspective of the Hong Kong healthcare system.
Methods
A Markov state-transition model was performed to estimate the incremental cost-effectiveness ratio (ICER) per quality-adjusted life years (QALYs) for DOACs and LMWH in a hypothetical cohort of 10,000 patients with CAT over a 5-year lifetime horizon. The model was primarily based on the health states of no event, recurrent venous thromboembolism, bleeding, and death. Transition probabilities, relative risks, and utilities were derived from the literature. Resource cost data were obtained from the Hong Kong Hospital Authority. Deterministic and probabilistic sensitivity analyses tested the robustness of the results.
Results
Relative to LMWH, DOACs were associated with increased QALYs (1.52 versus 1.50) at a lower medical cost of USD 2,232 versus 8,224 in five years. The cost of LMWH was the main contributor to the outcome. Out of 10,000 simulated cases, DOACs were dominant in 15.8% and cost-effective in 42.1%, at the willingness-to-pay threshold of USD 148,392 per additional QALY.
Conclusions
DOACs were associated with greater QALY improvements and lower overall costs compared to LMWH. Accounting for uncertainty, DOACs were between cost-effective and dominant in 57.9% of cases. DOACs are a cost-effective alternative to LMWH in the management of CAT in Hong Kong.
Direct oral anticoagulants (DOACs) have demonstrated clinical benefits and better patient adherence over low-molecular-weight heparin (LMWH) in treating patients with cancer-associated venous thrombosis (CAT). We aimed to compare the cost-effectiveness of DOACs against LMWH in patients with CAT from the perspective of the Hong Kong healthcare system.
Methods
A Markov state-transition model was performed to estimate the incremental cost-effectiveness ratio (ICER) per quality-adjusted life years (QALYs) for DOACs and LMWH in a hypothetical cohort of 10,000 patients with CAT over a 5-year lifetime horizon. The model was primarily based on the health states of no event, recurrent venous thromboembolism, bleeding, and death. Transition probabilities, relative risks, and utilities were derived from the literature. Resource cost data were obtained from the Hong Kong Hospital Authority. Deterministic and probabilistic sensitivity analyses tested the robustness of the results.
Results
Relative to LMWH, DOACs were associated with increased QALYs (1.52 versus 1.50) at a lower medical cost of USD 2,232 versus 8,224 in five years. The cost of LMWH was the main contributor to the outcome. Out of 10,000 simulated cases, DOACs were dominant in 15.8% and cost-effective in 42.1%, at the willingness-to-pay threshold of USD 148,392 per additional QALY.
Conclusions
DOACs were associated with greater QALY improvements and lower overall costs compared to LMWH. Accounting for uncertainty, DOACs were between cost-effective and dominant in 57.9% of cases. DOACs are a cost-effective alternative to LMWH in the management of CAT in Hong Kong.
| Original language | English |
|---|---|
| Article number | 2375269 |
| Pages (from-to) | 2375269 |
| Number of pages | 18 |
| Journal | Journal of Pharmaceutical Policy and Practice |
| Volume | 17 |
| Issue number | 1 |
| Early online date | 17 Jul 2024 |
| DOIs | |
| Publication status | Published - 31 Dec 2024 |
Bibliographical note
© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/),Funding
This work was supported by the Hong Kong Research Grants Council under the General Research Fund (GRF) [grant no. 17108621]. The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data. We thank Lisa Y Lam, MJ, Department of Pharmacology and Pharmacy, The University of Hong Kong, for proofreading the manuscript. Ms. Lam was compensated for her contribution. We thank the Information Technology Services, the University of Hong Kong, for offering research computing facilities for the computations in this study.
| Funders | Funder number |
|---|---|
| Research Grants Council, University Grants Committee | |
| Information Technology Services | |
| University of Hong Kong | |
| General Research Fund of Shanghai Normal University | 17108621 |
Keywords
- Direct oral anticoagulants (DOACs)
- Markov state-transition model
- Quality-adjusted life years (QALYs)
- cancer-associated venous thrombosis (CAT)
- cost-effectiveness
- low-molecular-weight heparin (LMWH)